PolyPeptide Group AG Logo

PolyPeptide Group AG

A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.

PPGN | SW

Overview

Corporate Details

ISIN(s):
CH1110760852
LEI:
5067007JCKTPOX4G9758
Country:
Switzerland
Address:
Neuhofstrasse 24, 6340 Baar
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPeptide Group AG is a global Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company provides comprehensive services to pharmaceutical and biotech partners, supporting the development and manufacturing of both proprietary and generic products. PolyPeptide assists clients throughout the product lifecycle, from initial development to regulatory approval and commercial launch. A key focus is on innovation in large-scale production and sustainable manufacturing processes, such as green peptide chemistry, to enhance process performance while minimizing environmental impact.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-22 07:00
Regulatory News Service
PolyPeptide Group achieves significant milestone in Malmo expansion project
English 10.6 KB
2025-09-22 02:00
Regulatory News Service
PolyPeptide Group achieves significant milestone in Malmö expansion project
English 8.5 KB
2025-08-12 06:55
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 31.7 KB
2025-08-12 02:00
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 28.4 KB
2025-08-12 02:00
Earnings Release
PolyPeptide wächst im ersten Halbjahr 2025 um 24%, mit einer erfolgreichen Anla…
German 32.6 KB
2025-05-23 07:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 7.8 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 6.0 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide gibt Ausweitung des bestehenden Kreditrahmens bekannt
German 7.0 KB
2025-04-09 18:34
Post-Annual General Meeting Information
PolyPeptide announces results of the annual General Meeting 2025
English 9.3 KB
2025-03-19 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 7.1 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025
German 8.0 KB
2025-03-12 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB
2025-03-11 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB

Automate Your Workflow. Get a real-time feed of all PolyPeptide Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPeptide Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPeptide Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-09 N/A Non-Executive member Buy None 75,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 72,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 75,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 72,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 35,000.00 CHF
2023-11-10 N/A Executive member Buy None 51,250.00 CHF
2023-10-11 N/A Executive member Buy None 2,876,348.62 CHF
2023-10-10 N/A Executive member Buy None 371,202.96 CHF

Peer Companies

Company Country Ticker View
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea 222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.